Skip to main content
Psych Congress  

Characteristics, Healthcare Resource Use, and Healthcare Costs of Patients With Major Depressive Disorder Treated With Vortioxetine: An Analysis of a US Claims Database

Authors  
Larry Ereshefsky, PharmD, FCCP, BCPP
Kristian Tore Jørgensen, PhD
Jun Tang, PhD
Delphine Saragoussi, MD, MPH
Maëlys Touya, PharmD
Clément François, PhD
Sponsor  
Lundbeck LLC

This poster was presented at the 29th Annual U.S. Psychiatric & Mental Health Congress, held October 21-24, 2016, in San Antonio, Texas.

Objective: To describe patients with major depressive disorder (MDD) switching to vortioxetine, and examine healthcare resource use and costs in the 6-month periods before and after switching therapy from another antidepressant treatment.

Methods: US claims data (2010-2015) from Integrated Dataverse (Symphony Health Solutions) from adults (≥18 years) with MDD (≥2 diagnoses records) who were treated with vortioxetine (≥1 prescription) were examined. The index date was the switch date (prescription fill) from another antidepressant (≥1 prescription) to vortioxetine. Healthcare resource use and costs were compared for 6-month pre-index vs post-index periods.

Results: Among patients with MDD switching to vortioxetine (N=22,606), 74.0% were women and the mean ± SD age was 48±14 years; 74.3% had a commercial healthcare plan. The most common comorbidity diagnoses recorded in the 12-month pre-index period were anxiety disorders (12.8%) and substance-related disorders (12.2%); 68.4% of patients had no recorded comorbidities. In the 12-month pre-index period, 49.1% of patients used 1 antidepressant and 44.5% used 2 or 3 antidepressants; most commonly used were selective serotonin reuptake inhibitors (47.6%) and serotonin-norepinephrine reuptake inhibitors (27.4%). For the 6-month post-index vs pre-index periods, numerical differences were seen in the proportion of patients with ≥1 visit to a mental health professional (23.8% vs 25.3%), mean ± SD number of visits (1.2±4.0 vs 1.5±4.5), mean ± SD total healthcare costs ($9059±16,361 vs $10,508±24,791), and mean ± SD pharmacy costs ($3680±4792 vs $2371±4125).

Conclusions: Decreased healthcare resource use and total healthcare costs were found after switching from another antidepressant to vortioxetine.

Back to Top